TMC-Ag5

Importantly, the addition of Ag5 significantly increased radiation-induced cell death in hypoxic conditions associated with radioresistance. Together, these data demonstrate Ag5 is a potent and cancer specific agent which could be used effectively in combination with radiotherapy.

Ag5, comprising clusters of five silver atoms, is a recently developed therapeutic agent that has been demonstrated to selectively kill cells with high levels of ROS by catalyzing the ROS-dependent oxidation of thiol groups on thioredoxins, peroxiredoxins and targets of the glutathione pathway (1)...Conclusion Our results demonstrate that targeting glutathione and thioredoxin pathways is a viable strategy to overcome radiation resistance ‘difficult to treat’ tumours such as PDAC and GBM. In vivo studies are planned to validate clinical potential.